BK0649 Ophthalmology
- 1741.285
- +3.959+0.23%
Conn Bay (600572.SH): Cumulative repurchase of 51.45 million shares of the company
Glonghui, May 5, 丨 Conn Bay (600572.SH) announced that as of April 30, 2024, the company had repurchased a total of 51.46.45 million shares of the company's shares through centralized bidding transactions at the Shanghai Stock Exchange, accounting for 2.00% of the company's total share capital. The highest repurchase transaction price was 5.00 yuan/share, the lowest price was 4.08 yuan/share, and the total capital commission used was 245.9663 million yuan (excluding transaction fees such as stamp duty and transaction fees).
Express News | Hengrui launches GLP-1R/GIPR dual agonist weight loss phase III study
Taiji Group (600129): Short-term pressure under high base, optimistic about steady recovery throughout the year
Core view The company achieved revenue of 4.208 billion yuan in Q1, a year-on-year decrease of -4.96%; achieved net profit to mother of 247 million yuan, an increase of 5.05% over the previous year; achieved net profit of 218 million yuan after deduction of non-return to mother, same
Huasun Technology to Cancel 3.8 Million Repurchased Shares
Chinese drugmaker Chengdu Huasun Technology Group (SHE:000790) will cancel 3.8 million shares that the company repurchased, the company said in its filing on the Shenzhen Stock Exchange. The shares, w
Freda (600223): Net profit deducted from non-return mother in 24Q1, YOY +242.5%, cosmetics, steady bottom in the first quarter, optimistic about the company's successful state-owned enterprise reform
Incident: The company released its 2024 quarterly report, achieving revenue of 890 million yuan, yoy -30%, net profit to mother of 59 million yuan, yoy -54.4%, net profit deducted from non-return mother of 52 million yuan, yoy+242.
Jiangsu Jibeier Pharmaceutical (SHSE:688566) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Jiangsu Jibeier Pharmaceutical Co., Ltd.'s (SHSE:688566) robust earnings report didn't manage to move the market for its stock. Our analysis suggests that shareholders have noticed something concerni
North China Pharmaceutical Company.Ltd (SHSE:600812) Strong Profits May Be Masking Some Underlying Issues
North China Pharmaceutical Company.Ltd (SHSE:600812) just released a solid earnings report, and the stock displayed some strength. Despite this, our analysis suggests that there are some factors weak
Jingxin Pharmaceutical (002020): Finished drugs are stabilizing and increasing the dosage of new drugs for insomnia can be expected
The impact of the company's generic drug collection is basically clear, and performance is expected to grow steadily. The company promotes levetiracetam tablets, sertraline hydrochloride tablets, dispersible tablets, and salt by establishing a “split line” marketing model centered on the three major channels of neuropsychiatric, cardiovascular, and digestive systems
Express News | Sinqi Eye Medicine: Aier Eye Hospital Group and others have reached a cooperation with the company and will introduce low-concentration atropine in the near future
Express News | Sinqi Pharmaceutical: After 0.01% atropine sulfate eye drops were approved, the production line was uninterrupted for 24 hours
Huaxia Ophthalmology (301267): The 24Q1 performance growth rate has slowed, and the implementation of mergers and acquisitions is expected to increase annual results
Core view: Huaxia Ophthalmology announced the 2023 and 2024Q1 results. The company achieved operating income of 4,013 billion yuan in 2023, +24.12% year-on-year; net profit to mother was 666 million yuan, +29 million yuan year-on-year.
Jianghe Group (601886): The leading curtain wall player, Hengqiang Industry maintained rapid growth under pressure, and the dividend ratio increased dramatically
Incident: The company achieved revenue of 4,086 billion yuan in 2024Q1, an increase of 19.50%, and net profit to mother of 182 million yuan, an increase of 11.10%. After deducting net profit of non-return to mother, it was 177 million yuan, an increase of 21.87%. spot
Aier Ophthalmology (300015): 23 years of steady growth, 24Q1 under short-term pressure
Core view: Aier Ophthalmology reports 2023 and 2024Q1 results. In 2023, the company achieved operating income of 20.367 billion yuan, +26.43% year-on-year; net profit to mother was 3.359 billion yuan, year-on-year +
Freda (600223): Steady revenue growth deducts good non-profit performance
Core view: Incident: The company released a quarterly report. In 24Q1, it achieved revenue of 890 million yuan, -30.0% year on year; net profit to mother of 60 million yuan, or -54.4% year on year; net profit after deducting non-return to mother of 50 million yuan, +2 year on year
Opcom TV (300595): Multiple categories work together to achieve steady growth in performance
Maintain a prudent accumulation rating. 2024Q1 achieved revenue of 465 million yuan (+15.71%), net profit attributable to mother of 193 million yuan (+11.39%), net profit after deducting non-return to mother of 167 million yuan (+11.5 percent)
Freda (600223): Rapid balance and liability optimization, cosmetics profit margins have increased
Core view 24Q1 cosmetics business revenue was 544 million yuan, +15.14% year over year, including Yilian 200 million yuan, +17.45%, Dr. Eyre 294 million yuan, +20.63%. The company focused on the two major brands
Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
It's been a good week for Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (SZSE:002223) shareholders, because the company has just released its latest first-quarter results, and the shares gained 3
Puri Ophthalmology (301239): Under pressure from 23 years of high performance growth base, 24Q1 performance is under pressure
Core view: Puri Ophthalmology released 23 and 24Q1 results. In '23, the company achieved revenue of 2,718 billion yuan (+57.50%); net profit to mother of 268 million yuan (+1202.56%); deducted not to mother
Cube Pharmaceuticals (003020): Divestment of Cube Pharmaceuticals' Q1 performance continues to push forward R&D under apparent pressure
Incident: The company released its report for the first quarter of 2024. 2024Q1 achieved revenue of 334 million yuan (-58.90%), net profit to mother of 30 million yuan (-54.08% year over year), deducted from non-return to mother
Jianghe Group (601886): Non-net profit deduction continues to increase BIPV in 24Q1, and overseas sales have great potential
Event Overview: The company released its report for the first quarter of 2024. In 24Q1, it achieved revenue of 4,086 billion yuan, +19.5% year over year; net profit to mother of 182 million yuan, +11.1% year over year; net profit after deducting 1.77 million yuan